推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

… to the Plasma Membrane in Response to Tumor Necrosis Factor-{alpha}: A Key Mechanism for Vascular Endothelial Growth Factor Receptor-2 Transactivation by …

ON Spindel… - Arteriosclerosis, Thrombosis, and Vascular …, 2011 - Am Heart Assoc
Methods and Results— In response to physiological levels of ROS (10 ng/mL tumor necrosis
factor-α and 30 µmol/LH 2 O 2 ), TXNIP-TRX1 translocated to the plasma membrane in human
umbilical vein EC, with a peak at 30 minutes, as measured by immunofluorescence ...
All 2 versions

… , placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally …

[HTML] from jcojournal.orgNJ Robert, V Diéras, J Glaspy… - Journal of Clinical …, 2011 - jcojournal.org
... Antiangiogenic therapies such as bevacizumab (BV), an antibody to vascular endothelial growth
factor, have proven to be effective in improving ... the effectiveness of taxane (Tax) plus BV
combinations in the initial treatment of human epidermal growth factor receptor 2 (HER2 ...
Cited by 156 - Related articles - All 7 versions

Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering

K Kisko, MS Brozzo, J Missimer, T Schleier… - The FASEB Journal, 2011 - FASEB
ABSTRACT Receptor tyrosine kinases play essential roles in tissue development and
homeostasis, and ab- errant signaling by these molecules is the basis of many diseases. Understanding
the activation mechanism of these receptors is thus of high clinical relevance. We ...
Related articles - All 2 versions

Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion

H Noma, H Funatsu, T Mimura, S Eguchi… - American Journal of …, 2011 - Elsevier
BRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670
pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265
pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; ...
Related articles - All 3 versions

… controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients …

[HTML] from 171.66.121.246JR Hecht, T Trarbach, JD Hainsworth… - Journal of Clinical …, 2011 - 171.66.121.246
Patients and Methods Patients (N = 1,168) with previously untreated metastatic colorectal cancer
were randomly assigned 1:1 to receive FOLFOX4 plus PTK/ZK or placebo (ClinicalTrials.gov
identifier: NCT00056459). Stratification factors included WHO performance status (0 v 1 ...
Cited by 3 - Related articles - All 6 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451